1. Home
  2. SYM vs PRAX Comparison

SYM vs PRAX Comparison

Compare SYM & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Symbotic Inc.

SYM

Symbotic Inc.

HOLD

Current Price

$55.15

Market Cap

7.5B

Sector

Industrials

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

HOLD

Current Price

$327.50

Market Cap

8.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SYM
PRAX
Founded
2005
2015
Country
US
US
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.5B
8.6B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
SYM
PRAX
Price
$55.15
$327.50
Analyst Decision
Hold
Strong Buy
Analyst Count
13
15
Target Price
$54.23
$519.60
AVG Volume (30 Days)
2.2M
425.7K
Earning Date
05-06-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$2,246,922,000.00
N/A
Revenue This Year
$24.66
N/A
Revenue Next Year
$27.88
$38,343.63
P/E Ratio
$2,707.00
N/A
Revenue Growth
25.65
N/A
52 Week Low
$16.32
$26.70
52 Week High
$87.88
$335.75

Technical Indicators

Market Signals
Indicator
SYM
PRAX
Relative Strength Index (RSI) 43.18 57.98
Support Level $53.06 $314.35
Resistance Level $64.41 $334.61
Average True Range (ATR) 4.18 17.67
MACD -0.10 -0.67
Stochastic Oscillator 31.46 76.50

Price Performance

Historical Comparison
SYM
PRAX

About SYM Symbotic Inc.

Symbotic Inc. is an automation technology company that develops solutions to improve operating efficiencies in modern warehouses. The group designs, commercializes, and deploys end-to-end technology systems that significantly enhance supply chain operations. The company automates the processing of pallets, cases, and individual items within warehouse environments. Its systems strengthen operations at the front end of the supply chain and provide benefits to all supply partners downstream. The company operates in two geographical regions: the United States and international markets, with the majority of its revenue generated in the United States.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.

Share on Social Networks: